Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AC Immune SA (NASDAQ: ACIU).

Full DD Report for ACIU

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACIU)

Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer's Treatment
Recently, Eli Lilly ( LLY ) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer's disease. This deal marks for a major push for the company to develop a treatment for this neurological disease where treatment op...
Source: SeekingAlpha
Date: December, 17 2018 08:51
Week 50 Breakout Forecast: Short-Term Picks To Give You An Edge
2018 YTD Chart: +38.68% The benchmark S&P 500 index continues into negative territory for 2018 with over 5% declines this past week. The Momentum Gauges The Momentum Gauge signals continue to maintain higher levels of negative momentum than positive momentum since week 39 (last we...
Source: SeekingAlpha
Date: December, 09 2018 13:12
In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with great sadness that we announce the passing of Dr. Andreas Muhs. Everyone at AC Immune will ...
Source: GlobeNewswire
Date: December, 07 2018 16:15
AC Immune to Present at 2018 Society for Neurosciences Meeting
Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases will provide updates on its product...
Source: GlobeNewswire
Date: November, 01 2018 06:00
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseases Meeting scheduled for November 5, 2018, from 12:00pm - 2:00pm ET AC Immune's Nasdaq Opening Bell ceremony takes place same day at 9:30am ET ...
Source: GlobeNewswire
Date: November, 01 2018 05:01
AC Immune partner Life Molecular Imaging presents clinical study results for Tau PET-Tracer 18F-PI-2620
AC Immune SA (NASDAQ: ACIU ) announces that its partner Life Molecular Imaging (LMI) has presented new clinical study results for 18F-PI-2620, a tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials. More news on: AC Immune...
Source: SeekingAlpha
Date: October, 29 2018 08:00
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
Study confirms the good performance of tau PET-tracer 18 F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11 th Clinical Trials on Alzheimer's Disease Conference (CTAD) in Barcelona, Spain, October 24...
Source: GlobeNewswire
Date: October, 29 2018 06:00
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's disease   Study on PET eligibility in CREAD Phase 3 showed excellent concordance betw...
Source: GlobeNewswire
Date: October, 29 2018 05:00
AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona
Lausanne, Switzerland, October 25, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has been selected for an oral presentation in the late breaking session at the 11 th annual Clinical ...
Source: GlobeNewswire
Date: October, 25 2018 04:00
Week 43 Breakout Forecast: Short-Term Picks To Give You An Edge
2018 YTD Chart: +49.00% Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 43: The Momentum Gauge conditions continue to worsen over the past several weeks since Week 39. The positive momentum gauge is now down to 7 from a value of 65 at the end of We...
Source: SeekingAlpha
Date: October, 22 2018 08:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-189.76610.02410.149.76613,307
2018-05-179.76610.02410.149.76613,307
2017-02-0212.0512.0912.22511.8542,456
2017-02-0112.2011.9812.3011.9847,005
2017-01-3111.8412.0212.3311.800131,609

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-179,03143,75520.6399Cover
2018-12-144,97320,25024.5580Cover
2018-12-138,26732,53725.4080Cover
2018-12-1222,97063,39036.2360Short
2018-12-116,88726,42426.0634Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACIU.


About AC Immune SA (NASDAQ: ACIU)

Logo for AC Immune SA (NASDAQ: ACIU)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $564,948,602 - 05/11/2018
  • Issue and Outstanding: 57,355,188 - 12/31/2017

 


Recent Filings from (NASDAQ: ACIU)

Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 04 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 22 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 22 2018

 

 


Daily Technical Chart for (NASDAQ: ACIU)

Daily Technical Chart for (NASDAQ: ACIU)


Stay tuned for daily updates and more on (NASDAQ: ACIU)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACIU)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACIU is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACIU and does not buy, sell, or trade any shares of ACIU. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/